Physician profile
Jack S Tuber
NPI 1306923750
$23,388.79
in general payments reported to CMS, 2019-2025
57 companies · $4,717 in 2025
The $4,717 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,884 · 2020: $1,629 · 2021: $2,015 · 2022: $2,997 · 2023: $3,637 · 2024: $4,510 · 2025: $4,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $1,184 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,436.82 |
| Travel and Lodging | $1,184.22 |
| Education | $243.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,099.27 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Ucb, INC. | $3,380.14 | 2019-2025 | Cimzia, Bimzelx |
| Amgen INC. | $3,051.53 | 2019-2025 | Tavneos, Evenity, Krystexxa |
| Janssen Biotech, INC. | $1,679.07 | 2019-2025 | Tremfya, Simponi Aria |
| Hexal Ag | $1,474.85 | 2019 | |
| Roche Products Limited | $1,424.22 | 2025 | |
| Mallinckrodt Hospital Products INC. | $1,142.19 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $944.98 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $877.27 | 2019-2025 | Benlysta, Nucala |
| E.R. Squibb & Sons, L.L.C. | $668.33 | 2019-2025 | Orencia |
| Radius Health, INC. | $629.91 | 2019-2025 | Tymlos |
| Genzyme Corporation | $478.46 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.83 | 2020-2025 | Ofev, Cyltezo, Jascayd |
| Ani Pharmaceuticals, INC. | $312.50 | 2022-2025 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $263.54 | 2023-2025 | Idacio, Tyenne |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Tuber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.